IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gopi VENKATESH, et al. Confirmation No.: 4820

Serial No.: 10/713,929 Group Art Unit: 1615

Filed: November 14, 2003 Examiner: David L. Vanik

For: MODIFIED RELEASE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

and 1.	7 0.				
	Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.				
	No copies of the publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.				
[X]	No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.				
	Publications listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to application serial no and mailed on				
	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).				

[.	Enclosed is a copy of a non-English publication(s) Engli publication (copy enclosed) claims priority from this publication.				
]	Enclosed is an explanation of non-English publication(s) for which an English translation is not available.			
]	Enclosed is an English translation of non-English publication(s) cited in the attached Form PTO/SB/08.			
	Enclosed is a copy of pending patent Application Serial No				
This Information Disclosure Statement is filed after the period specified in C.F.R. § 1.97(b), but before the mailing of:					
		[] a final action under 37 C.F.R. §1.113;			
		[X]	a notice	e of allowance under 37 C.F.R. §1.311; or	
			an actio	on that otherwise closes prosecution in this application.	
I	In accordance with 37 C.F.R. §1.97(c) also enclosed is:				
		[X]			
				Each item of information contained in the Information Disclosure Statement cited herein was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or	
				No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, having made a reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.	

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: January 3, 2008

COOLEY GODWARD KRONISH LLP ATTN: Patent Group 777 6th Street, N.W., Suite 1100 Washington, DC 20001

Tel: (202) 842-7800 Fax: (202) 842-7899 Respectfully submitted,

COOLEY GODWARD KRONISH LLP

By:

Thomas A. Blinka Reg. No. 44,541